Literature DB >> 17717251

Epidural, intrathecal pharmacokinetics, and intrathecal bioavailability of ropivacaine.

François-Xavier Rose1, Jean-Pierre Estebe, Maja Ratajczak, Eric Wodey, François Chevanne, Gilles Dollo, David Bec, Jean-Marc Malinovsky, Claude Ecoffey, Pascal Le Corre.   

Abstract

BACKGROUND: Ropivacaine is used by the epidural route for postoperative pain management with various neuraxial techniques. Given the widespread use of these techniques and the relative paucity of data on spinal disposition of local anesthetics, we evaluated through an experimental animal model, the spinal disposition of ropivacaine, allowing further studies of factors influencing their intrathecal bioavailability.
METHODS: Sheep received an IV bolus dose of ropivacaine (50 mg), and 1 wk after, an intrathecal dose of ropivacaine (20 mg) followed 3 h later by epidural ropivacaine (100 mg). A simultaneous microdialysis technique was used to measure epidural and intrathecal drug concentrations after both epidural and intrathecal administrations.
RESULTS: Absorption-time plots showed a large variability in the systemic absorption after both intrathecal and epidural administration, with an apparent faster systemic absorption after intrathecal administration. In the intrathecal space, the elimination clearance was around three-times higher than the distribution clearance. In the epidural space, the relative contribution of elimination and distribution to ropivacaine disposition was different, indicating a more pronounced influence of the distribution process. The intrathecal bioavailability after epidural administration was 11.1% +/- 7.6%.
CONCLUSIONS: Using an animal model, we showed that drug dispositions in the intrathecal and epidural compartments are different, and that the intrathecal bioavailability of ropivacaine after epidural administration is low, and highly variable.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17717251     DOI: 10.1213/01.ane.0000278129.37099.fa

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

1.  Human interleukin-10 delivered intrathecally by self-complementary adeno-associated virus 8 induces xenogeneic transgene immunity without clinical neurotoxicity in swine.

Authors:  Mark D Unger; Josef Pleticha; Lukas F Heilmann; Laura K Newman; Timothy P Maus; Andreas S Beutler
Journal:  J Gene Med       Date:  2018-06-15       Impact factor: 4.565

Review 2.  Analgesia for Sheep in Commercial Production: Where to Next?

Authors:  Alison Small; Andrew David Fisher; Caroline Lee; Ian Colditz
Journal:  Animals (Basel)       Date:  2021-04-14       Impact factor: 2.752

3.  Multi-Site Optical Monitoring of Spinal Cord Ischemia during Spine Distraction.

Authors:  David R Busch; Wei Lin; Chunyu Cai; Alissa Cutrone; Jakub Tatka; Brandon J Kovarovic; Arjun G Yodh; Thomas F Floyd; James Barsi
Journal:  J Neurotrauma       Date:  2020-07-20       Impact factor: 5.269

Review 4.  Epidural Oxycodone for Acute Pain.

Authors:  Panu Piirainen; Hannu Kokki; Merja Kokki
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

5.  Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain.

Authors:  Teng-Fei Li; Hui Fan; Yong-Xiang Wang
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

6.  Inadvertent Intrathecal Administration of Local Anesthetics Leading to Spinal Paralysis with Lipid Emulsion Rescue.

Authors:  Amit Gupta; Gabrielle L Procopio; Patrick H Charles; Monica Hernandez; Ruchi Patel
Journal:  Clin Pract Cases Emerg Med       Date:  2017-01-27

Review 7.  The Options for Neuraxial Drug Administration.

Authors:  Henning Hermanns; Elke M E Bos; Mark L van Zuylen; Markus W Hollmann; Markus F Stevens
Journal:  CNS Drugs       Date:  2022-07-15       Impact factor: 6.497

Review 8.  Thoracic epidural analgesia: a new approach for the treatment of acute pancreatitis?

Authors:  Olivier Windisch; Claudia-Paula Heidegger; Raphaël Giraud; Philippe Morel; Léo Bühler
Journal:  Crit Care       Date:  2016-05-04       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.